Oneness Biotech Co., Ltd. (4743.TWO)
TWD 57.1
(-9.37%)
TWD 57.1
(-9.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 866.42 Million TWD | 23.71% |
| 2022 | 700.38 Million TWD | -57.34% |
| 2021 | 1.64 Billion TWD | 1.05% |
| 2020 | 1.62 Billion TWD | 211.85% |
| 2019 | 520.96 Million TWD | 207.09% |
| 2018 | 169.64 Million TWD | 541.03% |
| 2017 | 26.46 Million TWD | -15.74% |
| 2016 | 31.4 Million TWD | -24.71% |
| 2015 | 41.71 Million TWD | -47.77% |
| 2014 | 79.86 Million TWD | -35.5% |
| 2013 | 123.81 Million TWD | 478.35% |
| 2012 | 21.4 Million TWD | 6.59% |
| 2011 | 20.08 Million TWD | 7.72% |
| 2010 | 18.64 Million TWD | 176.39% |
| 2009 | 6.74 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 835.58 Million TWD | -3.56% |
| 2024 Q2 | 807.62 Million TWD | -3.35% |
| 2023 Q4 | 866.42 Million TWD | 37.21% |
| 2023 FY | 866.42 Million TWD | 23.71% |
| 2023 Q1 | 687.35 Million TWD | -1.86% |
| 2023 Q2 | 704.03 Million TWD | 2.43% |
| 2023 Q3 | 631.47 Million TWD | -10.31% |
| 2022 Q1 | 1.65 Billion TWD | 0.86% |
| 2022 Q2 | 629.11 Million TWD | -62.0% |
| 2022 Q3 | 644.66 Million TWD | 2.47% |
| 2022 Q4 | 700.38 Million TWD | 8.64% |
| 2022 FY | 700.38 Million TWD | -57.34% |
| 2021 Q1 | 1.62 Billion TWD | 0.15% |
| 2021 FY | 1.64 Billion TWD | 1.05% |
| 2021 Q2 | 1.6 Billion TWD | -1.06% |
| 2021 Q3 | 1.61 Billion TWD | 0.34% |
| 2021 Q4 | 1.64 Billion TWD | 1.64% |
| 2020 Q4 | 1.62 Billion TWD | 2.01% |
| 2020 Q1 | 642.87 Million TWD | 23.4% |
| 2020 Q2 | 1.59 Billion TWD | 148.46% |
| 2020 Q3 | 1.59 Billion TWD | -0.29% |
| 2020 FY | 1.62 Billion TWD | 211.85% |
| 2019 Q2 | 524.82 Million TWD | 6.33% |
| 2019 FY | 520.96 Million TWD | 207.09% |
| 2019 Q3 | 576.2 Million TWD | 9.79% |
| 2019 Q1 | 493.56 Million TWD | 190.94% |
| 2019 Q4 | 520.96 Million TWD | -9.59% |
| 2018 Q1 | 17.79 Million TWD | -32.78% |
| 2018 FY | 169.64 Million TWD | 541.03% |
| 2018 Q4 | 169.64 Million TWD | 506.91% |
| 2018 Q3 | 27.95 Million TWD | 13.12% |
| 2018 Q2 | 24.71 Million TWD | 38.9% |
| 2017 Q1 | 25.51 Million TWD | -18.76% |
| 2017 Q3 | 25.22 Million TWD | 21.71% |
| 2017 Q2 | 20.72 Million TWD | -18.79% |
| 2017 Q4 | 26.46 Million TWD | 4.93% |
| 2017 FY | 26.46 Million TWD | -15.74% |
| 2016 FY | 31.4 Million TWD | -24.71% |
| 2016 Q4 | 31.4 Million TWD | -35.97% |
| 2016 Q3 | 49.04 Million TWD | 5.49% |
| 2016 Q2 | 46.49 Million TWD | 43.61% |
| 2016 Q1 | 32.37 Million TWD | -22.39% |
| 2015 Q1 | 69.38 Million TWD | -13.13% |
| 2015 FY | 41.71 Million TWD | -47.77% |
| 2015 Q3 | 40.7 Million TWD | -32.92% |
| 2015 Q4 | 41.71 Million TWD | 2.47% |
| 2015 Q2 | 60.68 Million TWD | -12.53% |
| 2014 Q2 | 125.54 Million TWD | 0.19% |
| 2014 Q1 | 125.3 Million TWD | 1.2% |
| 2014 FY | 79.86 Million TWD | -35.5% |
| 2014 Q4 | 79.86 Million TWD | -21.36% |
| 2014 Q3 | 101.56 Million TWD | -19.1% |
| 2013 FY | 123.81 Million TWD | 478.35% |
| 2013 Q4 | 123.81 Million TWD | 5.4% |
| 2013 Q3 | 117.47 Million TWD | 7.77% |
| 2013 Q2 | 108.99 Million TWD | 282.61% |
| 2013 Q1 | 28.48 Million TWD | 33.07% |
| 2012 Q4 | 21.4 Million TWD | -24.07% |
| 2012 Q1 | 35.6 Million TWD | 77.25% |
| 2012 Q2 | 38.41 Million TWD | 7.9% |
| 2012 FY | 21.4 Million TWD | 6.59% |
| 2012 Q3 | 28.19 Million TWD | -26.6% |
| 2011 Q3 | 23.16 Million TWD | 63.53% |
| 2011 Q4 | 20.08 Million TWD | -13.31% |
| 2011 Q1 | 14.7 Million TWD | -21.12% |
| 2011 Q2 | 14.16 Million TWD | -3.67% |
| 2011 FY | 20.08 Million TWD | 7.72% |
| 2010 FY | 18.64 Million TWD | 176.39% |
| 2010 Q4 | 18.64 Million TWD | 0.0% |
| 2009 FY | 6.74 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| SYN-TECH Chem. & Pharm. Co., Ltd. | 583.48 Million TWD | -48.493% |
| Level Biotechnology Inc. | 273.2 Million TWD | -217.14% |
| Sagittarius Life Science Corp | 137.82 Million TWD | -528.649% |
| NeoCore Technology Co., Ltd. | 197.47 Million TWD | -338.763% |
| TaiMed Biologics Inc. | 1.32 Billion TWD | 34.749% |
| GlycoNex Incorporation | 276.39 Million TWD | -213.47% |
| VBI | 21.25 Million TWD | -3977.121% |
| GeneReach Biotechnology Corp. | 313.7 Million TWD | -176.191% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 514.65 Million TWD | -68.353% |
| Visgeneer Inc. | 185.6 Million TWD | -366.813% |
| Mycenax Biotech Inc. | 1.32 Billion TWD | 34.521% |
| Sunmax Biotechnology Co., Ltd. | 732.98 Million TWD | -18.205% |
| G&E Herbal Biotechnology Co., Ltd. | 119.86 Million TWD | -622.868% |
| Medigen Vaccine Biologics Corporation | 2.24 Billion TWD | 61.425% |
| TaiwanJ Pharmaceuticals Co., Ltd. | 6.61 Million TWD | -12992.007% |
| Enimmune corporation | 173.46 Million TWD | -399.489% |
| TaiRx, Inc. | 60.62 Million TWD | -1329.161% |
| CHO Pharma, Inc. | 110.83 Million TWD | -681.75% |
| EirGenix Inc. | 1.14 Billion TWD | 24.336% |
| BioLASCO Taiwan Co., Ltd. | 111.98 Million TWD | -673.729% |
| Sunny Pharmtech Inc. | 512.43 Million TWD | -69.08% |
| Lin BioScience, Inc. | 167.73 Million TWD | -416.562% |
| BioGend Therapeutics Co., Ltd. | 93.71 Million TWD | -824.546% |
| Feng Chi Biotech Corp. | 63.03 Million TWD | -1274.542% |
| Bio Preventive Medicine Corp. | 124.72 Million TWD | -594.649% |
| Lukas Biomedical Inc. | 161.05 Million TWD | -437.958% |
| RBC Bioscience Corporation | 513.08 Million TWD | -68.868% |
| BiOptic Inc. | 170.56 Million TWD | -407.982% |
| BRIM Biotechnology, Inc. | 42.15 Million TWD | -1955.195% |
| Shine-On BioMedical Co.,Ltd. | 23.25 Million TWD | -3625.775% |
| Great Novel Therapeutics Biotech & Medicals | 26.81 Million TWD | -3131.377% |
| Syngen Biotech Co.,Ltd. | 974.63 Million TWD | 11.102% |
| Anti-Microbial Savior BioteQ Co., Ltd | 6.99 Million TWD | -12288.176% |
| SynCore Biotechnology Co.,Ltd | 21.22 Million TWD | -3981.923% |
| Genomics BioSci & Tech. Co.,Ltd. | 368.33 Million TWD | -135.231% |
| Neith Corporation | 17.43 Million TWD | -4870.051% |
| Advagene Biopharma Co., Ltd. | 7.97 Million TWD | -10768.402% |
| NaviFUS Corp. | 53.4 Million TWD | -1522.496% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 481.48 Million TWD | -79.949% |
| Sinew Pharma Inc. | 39.71 Million TWD | -2081.671% |
| Andros Pharmaceuticals Co.,Ltd | 58.03 Million TWD | -1392.839% |
| Greenyn Biotechnology Co., Ltd | 364.47 Million TWD | -137.719% |
| Lumosa Therapeutics Co., Ltd. | 227.69 Million TWD | -280.523% |
| AP Biosciences Inc | 106.65 Million TWD | -712.404% |
| Medigen Biotechnology Corp. | 3.53 Billion TWD | 75.456% |
| 3D Global Biotech Inc. | 30.68 Million TWD | -2723.992% |
| Pharmosa Biopharm Inc. | 195.99 Million TWD | -342.078% |
| Intech Biopharm Corporation | 1.54 Billion TWD | 43.856% |
| Eusol Biotech Co.,Ltd. | 9.27 Million TWD | -9240.545% |
| TWi Biotechnology, Inc. | 55.81 Million TWD | -1452.378% |
| Ever Supreme Bio Technology Co., Ltd | 232.95 Million TWD | -271.923% |
| TCI GENE Inc. | 155.54 Million TWD | -457.017% |
| MegaPro Biomedical Co., Ltd | 25.5 Million TWD | -3296.695% |
| Senhwa Biosciences, Inc. | 46.17 Million TWD | -1776.403% |
| Taiwan Bio Therapeutics Co., Ltd | 328.47 Million TWD | -163.777% |
| NatureWise Biotech & Medicals Corporation | 64.88 Million TWD | -1235.289% |
| PharmaEngine, Inc. | 91 Million TWD | -852.057% |
| Savior Lifetec Corporation | 457.95 Million TWD | -89.194% |
| TaiGen Biopharmaceuticals Holdings Limited | 110.94 Million TWD | -680.989% |
| OBI Pharma, Inc. | 650.44 Million TWD | -33.205% |
| Meribank Biotech Co., Ltd | 390.81 Million TWD | -121.7% |
| Acepodia, Inc. | 384.47 Million TWD | -125.356% |
| Caliway Biopharmaceuticals Co., Ltd. | 85.55 Million TWD | -912.739% |